Lynx1 Capital Management as of June 30, 2026
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 27 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gh Research Ordinary Shares (GHRS) | 41.2 | $357M | 13M | 26.88 | |
| Cullinan Oncology (CGEM) | 18.9 | $163M | 9.0M | 18.21 | |
| Stoke Therapeutics (STOK) | 15.3 | $132M | 4.0M | 32.72 | |
| Agios Pharmaceuticals (AGIO) | 14.6 | $127M | 3.4M | 37.11 | |
| C4 Therapeutics Com Stk (CCCC) | 4.0 | $34M | 7.3M | 4.67 | |
| Korro Bio (KRRO) | 2.3 | $20M | 1.5M | 13.18 | |
| Tscan Therapeutics (TCRX) | 0.9 | $7.9M | 8.0M | 0.98 | |
| Precision Biosciences Com New (DTIL) | 0.9 | $7.5M | 951k | 7.86 | |
| Neuphoria Therapeutics (NEUP) | 0.4 | $3.8M | 875k | 4.37 | |
| Passage Bio Com New (PASG) | 0.4 | $3.3M | 674k | 4.88 | |
| Cg Oncology (CGON) | 0.3 | $2.2M | 31k | 71.05 | |
| Pliant Therapeutics (PLRX) | 0.2 | $2.0M | 1.8M | 1.14 | |
| Entrada Therapeutics (TRDA) | 0.2 | $1.3M | 179k | 7.36 | |
| Vyne Therapeutics (VYNE) | 0.1 | $1.1M | 1.6M | 0.65 | |
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $970k | 521k | 1.86 | |
| Traws Pharma Com New (TRAW) | 0.1 | $472k | 560k | 0.84 | |
| Foghorn Therapeutics (FHTX) | 0.0 | $301k | 62k | 4.88 | |
| Denali Therapeutics (DNLI) | 0.0 | $300k | 12k | 25.72 | |
| Xencor (XNCR) | 0.0 | $293k | 18k | 16.10 | |
| Absci Corp (ABSI) | 0.0 | $246k | 21k | 11.59 | |
| Werewolf Therapeutics (HOWL) | 0.0 | $237k | 658k | 0.36 | |
| Immatics SHS (IMTX) | 0.0 | $235k | 23k | 10.13 | |
| Avalo Therapeutics Com New (AVTX) | 0.0 | $187k | 10k | 18.48 | |
| Bolt Biotherapeutics Com New (BOLT) | 0.0 | $119k | 31k | 3.85 | |
| Nuvation Bio Com Cl A (NUVB) | 0.0 | $91k | 16k | 5.68 | |
| Eupraxia Pharmaceuticals (EPRX) | 0.0 | $66k | 10k | 6.61 | |
| Inhibikase Therapeutics Com New (IKT) | 0.0 | $41k | 20k | 2.03 |
